Related references
Note: Only part of the references are listed.Targeting p53 pathways: mechanisms, structures, and advances in therapy
Haolan Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)
Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
Francesca Perutelli et al.
FRONTIERS IN ONCOLOGY (2022)
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
Eric M. Granowicz et al.
ONCOTARGETS AND THERAPY (2022)
Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children
Hanaa Skhoun et al.
MOLECULAR BIOLOGY REPORTS (2022)
Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children
Fan Liao et al.
BIOMED RESEARCH INTERNATIONAL (2022)
Association of Polymorphic Markers of the TP53, MDM2, and CDKN1A Genes with the Risk of Ovarian Cancer
P. K. Brenner et al.
RUSSIAN JOURNAL OF GENETICS (2022)
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Michael Hallek et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
p53 signaling in cancer progression and therapy
Hany E. Marei et al.
CANCER CELL INTERNATIONAL (2021)
Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes
Bartosz Slominski et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2021)
TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
Matteo Molica et al.
FRONTIERS IN ONCOLOGY (2021)
Chronic Lymphocytic Leukemia: Prognostic Factors at Presentation in a Resource-Limited Center
Kaladada Ibitrokoemi Korubo et al.
JCO GLOBAL ONCOLOGY (2021)
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries
Steven T. Bird et al.
JAMA ONCOLOGY (2020)
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia
Ke Shi et al.
CANCER MEDICINE (2020)
Targeting p53 in chronic lymphocytic leukemia
Riccardo Moia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Increase in Mortality and Second Neoplasms in Chronic Lymphocytic Leukemia with Pro/Pro Genotype of TP53 Codon 72
Martin Cabero-Becerra et al.
BLOOD (2020)
Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
Yan Qin et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Mutant p53 in Cancer Progression and Targeted Therapies
Gaoyang Zhu et al.
FRONTIERS IN ONCOLOGY (2020)
Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
Maria de Lourdes L. F. Chauffaille et al.
HEMATOLOGY TRANSFUSION AND CELL THERAPY (2020)
Evaluation of TP53 Codon 72, P21 Codon 31, and MDM2 SNP309 Polymorphisms in Iranian Patients with Acute Lymphocytic Leukemia
Ahmad Lotfi Garavand et al.
REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY (2020)
Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis
Xin Huang et al.
BIOSCIENCE REPORTS (2019)
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Lawrence A. Donehower et al.
CELL REPORTS (2019)
Association of the TP53 rs1042522 C>G polymorphism and hepatoblastoma risk in Chinese children
Tianyou Yang et al.
JOURNAL OF CANCER (2019)
Impact Of TP53 Gene Promoter Methylation On Chronic Lymphocytic Leukemia Pathogenesis And Progression
Waleed Haji Saeed et al.
JOURNAL OF BLOOD MEDICINE (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
Elias Campo et al.
HAEMATOLOGICA (2018)
Current prognostic and predictive factors in follicular lymphoma
Marc Sorigue et al.
ANNALS OF HEMATOLOGY (2018)
Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force
R. Stauder et al.
ANNALS OF ONCOLOGY (2017)
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
A. Stengel et al.
LEUKEMIA (2017)
The Transactivation Domains of the p53 Protein
Nitin Raj et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Chronic lymphocytic leukaemia
Thomas J. Kipps et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Significant association of TP53 Arg72Pro polymorphism in susceptibility to differentiated thyroid cancer
Mosin S. Khan et al.
CANCER BIOMARKERS (2015)
Increased Risk of Cutaneous Melanoma Associated with p53 Arg72Pro Polymorphism
Peiliang Geng et al.
PLOS ONE (2015)
TP53 Polymorphisms in Sporadic North Indian Breast Cancer Patients
Sarika Sharma et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia
Hua-Jie Dong et al.
MEDICAL ONCOLOGY (2014)
Evaluating the Association between p53 Codon 72 Arg>Pro Polymorphism and Risk of Ovary Cancer: A Meta-Analysis
Mohammed A. A. Alqumber et al.
PLOS ONE (2014)
Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis
Yu Lu et al.
TUMOR BIOLOGY (2014)
From pathogenesis to treatment of chronic lymphocytic leukaemia
Thorsten Zenz et al.
NATURE REVIEWS CANCER (2010)
p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia
Onoshua Lahiri et al.
CANCER GENETICS AND CYTOGENETICS (2007)
Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia
Geothy Kochethu et al.
LEUKEMIA RESEARCH (2006)
InB-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis -: art. no. 105
I Sturm et al.
BMC CANCER (2005)